Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mangalam Drugs & OrganicsNSE:MANGALAM +1.26%38 Debt-to-Equity is 1.02 as of Mar. 2026, which is 55% above its 10-year median of 0.66. GuruFocus rates NSE:MANGALAM with a GF Score™ of 38/100 and a GF Value™ of ₹62.06 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 812 Drug Manufacturers companies, Mangalam Drugs & Organics ranks worse than 85.34% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Mangalam Drugs & Organics's Debt-to-Equity or its related term are showing as below:
NSE:MANGALAM'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.5 Med: 0.66 Max: 1.02
Current: 1.02
During the past 13 years, the highest Debt-to-Equity Ratio of Mangalam Drugs & Organics was 1.02. The lowest was 0.50. And the median was 0.66.
NSE:MANGALAM's Debt-to-Equity is ranked worse than 85.34% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.275
vs NSE:MANGALAM: 1.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Mangalam Drugs & Organics Debt-to-Equity Related Terms
Mangalam Drugs & Organics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mangalam Drugs & Organics Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Mangalam Drugs & Organics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mangalam Drugs & Organics (NSE:MANGALAM) has a Debt-to-Equity of 1.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Mangalam Drugs & Organics and its competitors. This is 55% above median its historical median of 0.66. Over the past decade, Mangalam Drugs & Organics' Debt-to-Equity has ranged from 0.50 to 1.02. According to the industry distribution chart, Mangalam Drugs & Organics ranks #693 out of 812 companies in the Drug Manufacturers industry, placing it in the top 85.3%.
Is Mangalam Drugs & Organics' Debt-to-Equity too high?
Mangalam Drugs & Organics' current Debt-to-Equity of 1.02 is 55% above median its 10-year median of 0.66. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 1.02. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Mangalam Drugs & Organics' value of 1.02 is 270.9% above this industry median. Based on the distribution chart, Mangalam Drugs & Organics ranks #693 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mangalam Drugs & Organics has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mangalam Drugs & Organics ranks #693 out of 812 companies for Debt-to-Equity. This places Mangalam Drugs & Organics in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Mangalam Drugs & Organics' value of 1.02 is 270.9% above this benchmark. Historically, Mangalam Drugs & Organics' own Debt-to-Equity has ranged from 0.50 to 1.02 over the past decade. While the company's 10-year median is 0.66 vs. the industry median of 0.28, Mangalam Drugs & Organics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mangalam Drugs & Organics's current Debt-to-Equity of 1.02 is 270.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Mangalam Drugs & Organics and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mangalam Drugs & Organics's current Debt-to-Equity is 1.02, which is 55% above median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹62.06, compared to a current price of ₹27.27 — trading 56.1% below its estimated fair value. The current Debt-to-Equity is 1.02, which is 55% above median its 10-year median of 0.66 and 270.9% above the Drug Manufacturers industry median of 0.28. Mangalam Drugs & Organics' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Debt-to-Equity is 1.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?
Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued.
The current stock price of ₹27.27 is trading 56.1% below its estimated GF Value™ of ₹62.06.
GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.
Key valuation signals for NSE:MANGALAM:
Debt-to-Equity: 1.02 (55% above median its 10-year median of 0.66)
GF Value™: ₹62.06 vs. price of ₹27.27 (56.1% below fair value)
Industry Position: 270.9% above the Drug Manufacturers median (#693 of 812)
No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
38GF Score
Get the complete analysis for NSE:MANGALAM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MANGALAM has been successfully added to your 
